Pyridazinone compounds and methods for the treatment of cystic fibrosis

A compound of Formula I:

• wherein A1 is —[C(R100)(R101)]n—, —C(O)—, —C(S)—, —S(O)—, —C(O)N(R100)—, —S(O)2N(R100)—S(O)2—, carbocycle, substituted carbocycle, heterocycle, substituted heterocycle, aromatic, substituted aromatic, heteroaromatic or substituted heteroaromatic;
• wherein n is 0, 1, 2, 3, 4, 5, 6 or 7;
• wherein each R100 and R101 is hydrogen, deuterium, halogen, alkyl, substituted alkyl, heteroalkyl, substituted heteroalkyl, alkenyl, substituted alkenyl, alkynyl, substituted alkynyl, aliphatic, substituted aliphatic, aryl and substituted aryl;
• alternatively two of R100 and R101 groups together with the atoms to which they are attached and any intervening atoms may form an additional optionally substituted, 3, 4, 5, 6 or 7 membered ring;
• A2 is absent, —[C(R100)(R101)]n—, —C(O)—, —C(S)—, —S(O)—, —C(O)N(R100), —C(O)N(R100)(R101), N(R100)(R101), —S(O)2—, —S(O)2R100, —S(O)R100, —S(O)2N(R100)R101),
• A3 is absent, —[C(R100)(R101)]n—, —C(O)—, —C(S)—, —S(O)—, —C(O)N(R100)—, —C(O)N(R100)(R101), N(R100)(R101), —S(O)2—, S(O)2R100, S(O)R100, S(O)2N(R100)R101);
• Cy2 is an aryl, substituted aryl, carbocycle, substituted carbocycle, heterocyclyl, substituted heterocyclyl, heteroaryl, or substituted heteroaryl group having one, two or three rings wherein said rings may be fused or bridged rings;
• Cy1 is absent, an aryl, substituted aryl, carbocycle, substituted carbocycle, heterocyclyl, substituted heterocyclyl, heteroaryl, or substituted heteroaryl group having one, two or three rings;
• and
• Cy3 is absent, an aryl, substituted aryl, carbocycle, substituted carbocycle, heterocyclyl, substituted heterocyclyl, heteroaryl, or substituted heteroaryl group having one, two or three rings.